Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing
Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

June 23, 2025 Capital Markets and Public M&A

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.

Hansa Biopharma AB is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Annie Fällström and Amanda Sandström.

Related

Vinge has advised Bolero in connection with sale of shares in Ambea AB (publ)

 Vinge has advised Bolero Holdings S.à r.l. in connection with the sale of shares in Ambea AB (publ) through an accelerated bookbuilding process carried out on 1 December 2025.
December 02, 2025

Vinge advises on the sale of Segers Fabriker

 Vinge has advised the sellers in connection with the sale of Segers Fabriker AB to Norrstigen. Segers is a family-owned company in Borås with operations in Sweden, Estonia, and Ukraine, which has developed and sold workwear for hotels, restaurants, and healthcare since 1943.
December 02, 2025

Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million

 Vinge has advised the property company Intea Fastigheter AB (publ) in connection with a directed share issue of shares of series D through which the company raises proceeds of approximately SEK 500 million before transaction costs. A part of the share issue is subject to subsequent approval at an extraordinary general meeting.
December 01, 2025